In an effort to hike up radiochemotherapy dose and improve lung cancer survival, oncologists have been looking for higher-precision alternatives to F-18 FDG PET, which experiences issues with tumor shrinkage and alterations in uptake during treatment. However, emerging F-18 labeled alternatives fluorothymidine (FLT) and fluoromisonidazole (FMISO) show relatively low interobserver agreement when characterizing tumor volumes and require special standardization, according to a French multi-center study published August 5 in the Journal of Nuclear Medicine.

Mental disorders including schizophrenia, bipolar disorder and major depression have some common genetic variants that account for significant risk of crossover disease, according to research published August 11 in Nature Genetics.

The Minneapolis-based outpatient imaging center network Center for Diagnostic Imaging (CDI) has expanded its regional presence in Massachusetts with the acquisition of The MRI Centers of New England

The CMS final rule on 2014 Medicare rates for the Inpatient Prospective Payment System (IPPS) cuts advanced imaging reimbursement through changing the cost-to-charge ratios for CT and MR services

For older people showing signs of cognitive impairment, doctors could one day prescribe a daily dose of chocolate. New research shows regular cocoa consumption in the elderly led to significantly better neuronal metabolic function and blood flow, and subsequently improved cognition, according to a study published August 7 in Neurology.

Radioimmunotherapy (RIT) has not been able to gain traction for a majority of solid tumor types, but new evidence could put Cu-64 labeled DOTA-cetuximab in line for difficult-to-treat colorectal tumors with specific genetic mutations, according to a study published July 19 in the Journal of Nuclear Medicine.

Angiogenesis is a hallmark of invasive cancer and antiangiogenesis therapies are gaining momentum, but some patients do not respond well. F-18 FLT may be the strongest contender out of three F-18 labeled PET agents used to evaluate early response to therapy, which aims to improve patient management and negate unnecessary treatments, according to research published August 1 in the Journal of Nuclear Medicine.

Just under 450 new therapies are in the works for a wide range of neurological disorders, including Alzheimer’s  and Parkinson’s disease, brain cancer, epilepsy, multiple sclerosis and many others, according to a 2013 report released Wednesday by PhRMA, a biopharmaceutical industry trade group.